Organisation: Federal Trade Commission (USA)

Nevo: market power omission not critical change

The Federal Trade Commission’s top economist is pushing back against criticism that draft merger guidelines have ditched a focus on market power in favour of concentration.

06 September 2023

FTC settles Amgen/Horizon challenge

Amgen and Horizon Therapeutics can proceed with their $27.8 billion merger after entering a settlement with the Federal Trade Commission that prevents the new company from bundling Horizon’s rare disease treatments.

05 September 2023

FTC loses appeal against Endo-Impax agreement

The Federal Trade Commission failed to demonstrate that a settlement between Endo Pharmaceuticals and Impax Laboratories caused anticompetitive harm beyond what US patent law allows, an appellate panel has said.

29 August 2023

Biden administration enforcement policy creates challenging environment for US mergers

Featured in Americas Antitrust Review 2024

An executive order has directed national agencies to re-evaluate their merger guidelines and take a hard look at whether they are overly permissive, which looks set to increase scrutiny on current mergers.

25 August 2023

US DOJ tests new approaches to boost cartel enforcement revival efforts

Featured in Americas Antitrust Review 2024

Amid struggles to identify and punish large domestic and international cartels, the Department of Justice is stepping up through new focus areas such as monopolisation and AI.

25 August 2023

Biden administration and US antitrust agencies balance IP protection with competition concerns

Featured in Americas Antitrust Review 2024

The DOJ and FTC are discouraging injunctions and other exclusionary remedies favoured by standard essential patent holders as part of a significant shift in antitrust enforcement from the Trump to Biden administration.

25 August 2023

Antitrust scrutiny of US labour markets intensifies

Featured in Americas Antitrust Review 2024

The Biden administration is turning up the heat on anti-competitive activity in the employment space, promoting federal agency rulemaking to curtail perceived harmful practices.

25 August 2023

FTC v Actavis and pricing practices spearhead rise in US pharmaceutical antitrust cases

Featured in Americas Antitrust Review 2024

New legislation and legal challenges in the life sciences industry are yielding a plethora of cases – specifically in regard to reverse-payment and product-hopping – grabbing the attention of leading producers and everyday consumers.

25 August 2023

US DOJ and FTC intensely scrutinise mergers in technology and pharmaceutical industries

Featured in Americas Antitrust Review 2024

The US antitrust agencies – whose influence will soon grow thanks to revised merger guidelines – are increasingly unified in rooting out potentially anticompetitive mergers in the technology and pharmaceutical sectors.

25 August 2023

Economist’s perspective: US antitrust regulators focus on defining relevant labour markets

Featured in Americas Antitrust Review 2024

Defining markets is increasingly critical to US efforts to measure and regulate market power, protect workers and nip anticompetitive actions in the bud.

25 August 2023

Unlock unlimited access to all Global Competition Review content